General Information

Targeting Microbiota 2024: Confirmed Speakers

Keynote Speech Day 1  Phage Therapy: A New Era of “Old” Concept for “Microbiome” Health Mzia Kutateladze, Eliava Institute of Bacteriophage, Georgia

Keynote Speech Day 2  The Mystery of the Microbiome Genome: The Potential of 2 to 20 Million Microbial Genes to Transform Our Health Marvin Edeas, Institut Cochin, INSERM U1016, Université de Paris, France

Gut Microbiome, Obesity and Diabetes Hiroshi Ohno, RIKEN Center for Integrative Medical Sciences, Japan

Mythbusting Our Microbiome Alan Walker, University of Aberdeen, United Kingdom

Probiotics & Health: How to Select the Right Strain? Andreas Schwiertz, Institute of Microecology, Germany

Gut Brain Axis & Depression: Startegic Role of Dietary Proline Exposed José Manuel Fernández-Real, Institut d'Investigació Biomèdica de Girona, Hospital Trueta de Girona, and University of Girona, Spain

The Small Intestinal Microbiota: A Hidden Player in Human Health and Disease Pascale Vonaesch, University of Lausanne, Switzerland

Microbiota-Derived Extracellular Vesicles: Bridging Mother and Fetus Justus Reunanen, University of Oulu, Finland

Male Fertility And Gut Microbiota: Current Knowledge And Future Directions Cristian O'Flaherty, McGill University, Canada

Microbial Phenotypes in Obesity: Implications for Precision Nutrition Ellen Blaak, Maastricht University, Netherlands

Bacteriophages Redesigned – Tiny Killers and Detectives to Support Infectious Disease Therapy Martin Loessner, ETH Zurich, Switzerland

Prospects for Leveraging the Microbiota as Medicine for Hypertension Bina Joe, University of Toledo, USA

Sophisticated in vitro Models of the Gastrointestinal Tract to Study the Role of the Gut Microbiota in Health and Disease Koen Venema, Editor-in-chief of Beneficial Microbes, Netherlands

Gut Microbiota in Early Life: Impact on Neurodevelopmental Outcomes Rochellys Diaz Heijtz, Karolinska Institutet, Sweden

Gut Bacteria and Heart Healing: The Hidden Players in Post-Infarction Resilience Patrick C. H. Hsieh, Academia Sinica, Tawian

The Oral-Placental Microbiome Axis in Preterm Birth Souhaila Al Khodor, Sidra Medicine, Qatar

Gut Microbiome Signatures in Irritable Bowel Syndrome Simone Domenico Guglielmetti, Università degli Studi di Milano-Bicocca, Italy

From Microbiomes and (Meta)genomes to the Lab and Back - Identification, Production and Application of Bacteriocins Christian Riedel, University of Ulm, Germany

Who is Attending Targeting Microbiota 2024?

17/05/2024

Targeting Microbiota 2016 - Preliminary Agenda

4th World Congress on

Targeting Microbiota 

Towards Clinical Revolution

October 17-19, 2016 - Institut Pasteur - Paris, France

Preliminary Agenda

Among speakers already confirmed:

Bioinformatics, integrating clinical and microbiome data: the challenge.
Examples from gut, oral and nasal microbiota in Parkinson’s disease
Velma Aho, University of Helsinki, Finland

Transition from an infant- to adult-like gut microbiota – where do the bacteria come from?
Ekaterina Avershina, Norway University of Life Sciences, Norway

Changing of skin and gut Microbiotas in ordinary life: cosmetics and bowel
Lorenzo Drago, University of Milan, Italy

Moody microbes or fecal phrenology: what do we know about the microbiota-gut-brain axis?
Paul Forsythe, McMaster University, Canada

Age-related immune senescence and microbiota dysbiosis: lessons from the fly
Henri Jasper, University of Rochester, USA

Impact of microbiota on odorant detection and olfactory preferences in mice
Nicolas Meunier, Neurobiologie de l'Olfaction et Blosenseur (NBO), INRA

Functional Redundancy-Induced Stability of Gut Microbiota Subjected to Disturbance
Andrés Moya, University of Valencia, Spain

Faecalibacterium prausnitzii dynamics in the human gut microbiome underlying atopic dermatitis
Heenam Stanley Kim, Korea University, Republic of Korea

Maternal microbiota sets neonatal innate immune system development
Mercedes Gomez de Agüero, University of Bern, Switzerland

Microbiota & Bioinformatics: Strategic Targets
Sean Kennedy, Institut Pasteur, Paris

Emerging role of fecal microbiota therapy in the treatment of gastrointestinal diseases
Peter C. Konturek, Thuringia-Clinic Saalfeld, Germany

Lactobacillus rhamnosus GG intake modifies preschool children’s intestinal microbiota, alleviates penicillin-associated changes and reduces antibiotic use
Katri Korpela, Helsinki University, Finland

Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics
Roberto Pacifici, Emory University School of Medicine, USA

Tools and approaches to achieve strain resolution analyses of the microbiota
The gut microbiota mobilome and the potential of pathogen transmission of antibiotic resistance
Knut Rudi, Norway University of Life Sciences, Norway

Efficacy and mechanisms of action of fecal microbiota transplantation in ulcerative colitis: Pitfalls and promises from a first meta-analysis
Franco Scaldaferri, Catholic University of Sacred Hearth, Italy

Bacteriophages for improving human health: from food additives to dietary supplements
Alexander Sulakvelidze, Intralytix, USA

Mammals shape their microbiome to prevent disease: Recent Scientific advances & Perspectives
Howard Weiner, Harvard Medical School, USA

Important human microbial ecological system modulator - FMT (fecal microorganism transplantation) or one of the best clinical applications of epigenetics in gastroenterology
Diana Zandere, University of Riga, Latvia

Bacteriocin from epidemic Listeria strains alters the host intestinal microbiota to favor infection
Juan-Jose Quereda, Institut Pasteur, France

Response of gut bacteria to host starvation: understanding the risk factos to develop an eating disorder
Serguei Fetissov, Rouen University, France

Day 1 - October 17

Session 1: Microbiota 2016: Recent Advances & Perspectives

• Mechanistics
• Cellular & Molecular Impacts
• Microbiota & Immunity: The subtle balance
• Microbiota & Mitochondria: The intriguing relationship

Session 2: Microbiota analysis 2016: The challenge of big data interpretation

• How to manage the big data?
• Focus 2016: Strategic role of bio-informaticians to interpret the results
• Microbiota & Bioinformatics: Strategic targets

Session 3: Skin Microbiota: Recent advances and perspectives

Day 2 - October 18

Session 4: Challenges to control the diversity and variability of microbiota by:

• Phage therapy
• Diet, probiotics and prebiotics
• CRISPR/Cas system
• Quorum sensing
• Fecal Microbiota Transplantation

Day 3 - October 19

Focus on Fecal Microbiota Transplantation: Clinical & Practical Issues

Session 5: Microbiota & Clinical Studies: Recent results

The details of each session will be available soon.

To access to the list of speakers already confirmed, please click here.

Deadlines for...

 Early Bird Registration Fees: September 17^th

Short Oral Presentations Submission: September 17^th

Award Submission: September 17^th

Poster Presentations Submission: October 15^th

Antioxidants 2013 & First Moroccan Exhbition will offer you a lot of Opportunities

Read more...

CME & Certificate Delivery

Targeting Mitochondria 2012 is endorsed by ISANH, SFA and JSA . At your request, you will receive a participation certificate attesting your presence at Targeting Mitochondria 2012.

Targeting Mitochondria 2012 will be endorsed by the European Accreditation Council for Continuing Medical Education (EACCME).

More information about credits soon...

blocs

Medicinal Plants & Ethno-Medicine First Symposium

The First symposium on Medicinal Plants & Ethno-Medicine will be held on third day of Antioxidants 2013 International Conference, on June 28, 2013.

The aim of the first symposium on Medicinal Plants & Ethno-Medicine is to gather east and western traditional medicine to discuss the oppositions and challenges about all medicinal plants mainly in Africa and all around the world, but also their potential of applications in medicine.

Read more...